Mastodon

Trekresil® (Tablets) Instructions for Use

Marketing Authorization Holder

Rionipharm LLC (Russia)

Manufactured By

Aromasintez, LLC (Russia)

ATC Code

A13A (General tonic preparations)

Active Substance

Oxyethylammonium methylphenoxy acetate (Grouping name)

Dosage Form

Bottle OTC Icon Trekresil® Tablets 200 mg: 10, 20, 30 or 50 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish tint, round, flat-cylindrical, with a bevel and a score line.

1 tab.
Oxyethylammonium methylphenoxy acetate 200 mg

Excipients: lactose monohydrate – 200 mg, potato starch – 95 mg, calcium stearate – 5 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.

Clinical-Pharmacological Group

Preparation with adaptogenic and restorative action

Pharmacotherapeutic Group

Adaptogenic agent

Pharmacological Action

Adaptogenic agent. Stimulates the production of alpha and gamma interferons, affects the immune status of the body by activating the cellular and humoral links of immunity, stimulates the phagocytic activity of macrophages.

It strengthens the body’s immune system, increases endurance during physical and mental stress, reduces the effect of various toxins, increases the body’s resistance to hypoxia, low and high temperatures and other adverse environmental factors.

Pharmacokinetics

Oxyethylammonium methylphenoxy acetate has high bioavailability, is rapidly metabolized in the liver, and is excreted by the kidneys mainly in the form of glucuronides. It does not accumulate in the body with long-term use.

Indications

As part of complex therapy: for the prevention and treatment of acute respiratory viral infections; during periods of high intellectual and heavy physical exertion; to increase the body’s resistance to various stressful influences (hypoxia, overheating, hypothermia) and adverse environmental influences (sudden climate change, adaptation to changes in atmospheric pressure).

ICD codes

ICD-10 code Indication
J06.9 Acute upper respiratory infection, unspecified
T67 Effects of heat and light
T68 Hypothermia
T70 Effects of air pressure and water pressure
Z57 Occupational exposure to risk factors
Z73.3 Stress, not elsewhere classified (physical and mental strain)
ICD-11 code Indication
CA07.0 Acute upper respiratory tract infection of unspecified site
NF01.Z Exposure to heat, unspecified
NF02 Hypothermia
NF04.Z Exposure to atmospheric pressure and water pressure, unspecified
QD84.Z Exposure to occupational risk factors, unspecified
QE01 Stress, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer Trekresil®orally with water.

For acute respiratory viral infections (ARVI) prevention and treatment, take 200 mg (1 tablet)twice daily for a 10-day course.

To manage high intellectual or physical stress, take 200 mg (1 tablet)once or twice daily. Limit the course duration to two weeks.

For enhancing resistance to stressful environmental factors (e.g., climate change, hypoxia), initiate a 200 mg (1 tablet)once or twice daily regimen 1-2 days prior to expected exposure. Continue throughout the exposure period.

Do not exceed a single dose of 200 mg or a daily dose of 400 mg.

For patients with hepatic or renal impairment, no dose adjustment is required.

Discontinue use if severe disease symptoms persist or worsen and consult a physician.

Adverse Reactions

Rarely allergic reactions – hypersensitivity reactions, anaphylactic shock, anaphylaxis, angioedema.

Contraindications

Hypersensitivity to the active substance; children under 12 years of age; pregnancy, breastfeeding period.

Use in Pregnancy and Lactation

Use is contraindicated during pregnancy and breastfeeding.

Use in Hepatic Impairment

The drug is approved for use in patients with impaired liver function.

Use in Renal Impairment

The drug is approved for use in patients with impaired renal function.

Pediatric Use

Use in children under 12 years of age is contraindicated (due to the lack of data on efficacy and safety of use).

Geriatric Use

Use in elderly patients is permitted.

Special Precautions

If, during the use of the product, pronounced symptoms of the disease persist or worsen in patients with ARVI, the product should be discontinued and a doctor should be consulted.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS